Figure 5.

Blocking the Klf5/Cox2 axis potentiates the antitumorigenic effects of anti-PD1 blockade. (A) Mice inoculated with control or Klf5-deficient EMT6 cells were treated every three days with anti-Pd1 blocker (total 3 times) when tumors were approximately 20 mm² in mean area. Growth curves (mean ± SEM), tumor size distributions at Day 17, individual tumor growth curves and survival curves are shown. (B) Mice inoculated with control EMT6 cells were continuously treated for three or two days with FZU00,004 for two weeks with or without an anti-Pd1 blocker when tumors were approximately 20 mm² in mean area. Growth curves (mean ± SEM), tumor size distributions at Day 17, individual tumor growth curves of mice and survival curves are shown. (C) Mice inoculated with control EMT6 cells were continuously treated with CEL for two weeks with or without an anti-Pd1 blocker when tumors were approximately 20 mm² in mean area. Growth curves (mean ± SEM), tumor size distributions at Day 20, individual tumor growth curves and survival curves are shown. n ≥ 8 for mice in each group. (*p < 0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001 or ns, not statistically significant vs. control; two-way ANOVA). The generation of immunological memory was assessed in cured animals by rechallenge with EMT6 and CT26. A fresh mouse (n = 1) was synchronously challenged with EMT6 and CT26 as a control.